Based on BioExpress technology
AET BioTech, the biosimilars business of generic drug developer Alfred E Tiefenbacher (AET), has agreed with Swiss biotech BioXpress Therapeutics to co-develop a biosimilar version of the TNF inhibitor MAb Adalimumab.
The firms will be jointly responsible for the development, registration and manufacture of the biosimilar, which is based on BioXpress technology.
Hamburg, Germany-based AET BioTech will also be responsible for providing further investment through long-term financing and for any future commercialisation of the product.
Abbott currently markets Adalimumab, which in 2011 had global sales of more than US$$7.9bn.
‘The BioXpress team has an impressive track record in the development of the initial originator MAbs, and access to state-of-the-art MAb know-how and technology, and the partnership will unite our technical and commercial strengths behind the Adalimumab biosimilar,’ said Dr Harm Peters, MD of AET BioTech.
‘The cooperation with BioXpress on our initial project is a key step in AET BioTech\'s mission to bring European quality biosimilar drugs to markets worldwide at fair prices.’